Torrent Pharmaceuticals
Torrent Pharmaceuticals Share Price Chart
Torrent Pharmaceuticals last traded at ₹4,654.90 (2026-10-13). Over the past month the stock moved -5.5%, three months the stock moved +4.6%, year the stock moved +28.2%. Its closing range over 52 weeks is ₹3,559.10 – ₹5,035.00, with the latest close 7.5% below the high.
Closing prices up to 2026-10-13.
About Torrent Pharmaceuticals
Torrent Pharmaceuticals Ltd is one of the leading Indian Pharmaceutical Company engaged in research, development, manufacturing and marketing of generic pharmaceutical formulations.[1]
Product Segment FY26: a) Branded Generics (74%):[1] The company’s branded generics business focuses on the manufacturing pharmaceutical products under its brand names catering to various therapeutic segments including cardiovascular, central nervous system, gastrointestinal, vitamin mineral nutrients, dermatology, diabetes, pain management and gynecology. Its branded generic medicines are marketed in key regions including India and Brazil.[2] b) Generics (26%): The generics segment specializes in manufacturing and supplying generic pharmaceutical products, particularly in the markets where patent exclusivity has expired or regulatory approval allows for the production of generic versions of branded drugs. This segment focuses on specific markets, including emerging and regulated ones like the US, Europe, etc. [3]
Fundamentals
Quarterly Results
In the latest quarter (Jun 2026), Torrent Pharmaceuticals reported sales of ₹4,921.00 crore (+54.8%) and net profit of ₹566.00 crore (+3.3%), compared with the same quarter last year.
| Period | Sales | Operating profit | OPM % | Net profit | EPS (₹) |
|---|---|---|---|---|---|
| Jun 2026 | 4,921 | 1,664 | 34.00 | 566.00 | 16.72 |
| Mar 2026 | 4,197 | 1,356 | 32.00 | 364.00 | 10.76 |
| Dec 2025 | 3,303 | 1,088 | 33.00 | 635.00 | 18.76 |
| Sep 2025 | 3,302 | 1,083 | 33.00 | 591.00 | 17.46 |
| Jun 2025 | 3,178 | 1,032 | 32.00 | 548.00 | 16.19 |
| Mar 2025 | 2,959 | 964.00 | 33.00 | 498.00 | 14.71 |
| Dec 2024 | 2,809 | 914.00 | 33.00 | 503.00 | 14.86 |
| Sep 2024 | 2,889 | 939.00 | 32.00 | 453.00 | 13.38 |
| Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Sales growth | +8.6% | +2.8% | +7.8% | +11.2% | +14.3% | +17.6% | +41.8% | +54.8% |
| Operating profit growth | +13.8% | +5.2% | +9.2% | +14.2% | +15.3% | +19.0% | +40.7% | +61.2% |
| Net profit growth | +17.4% | +13.5% | +10.9% | +19.9% | +30.5% | +26.2% | -26.9% | +3.3% |
| EPS growth | +17.3% | +13.5% | +10.9% | +19.9% | +30.5% | +26.2% | -26.9% | +3.3% |
| OPM % | 32.0% | 33.0% | 33.0% | 32.0% | 33.0% | 33.0% | 32.0% | 34.0% |
Colour scale: below -5% -5% to 0% 0% to 5% 5% to 20% 20% and above. A dash means the earlier figure was zero or negative, so a percentage is not meaningful.
Annual Financials
In the latest year (Mar 2026), Torrent Pharmaceuticals reported sales of ₹13,980.00 crore (+21.4%) and net profit of ₹2,138.00 crore (+11.9%), compared with the previous year.
| Period | Sales | Operating profit | OPM % | Net profit | EPS (₹) |
|---|---|---|---|---|---|
| Mar 2026 | 13,980 | 4,559 | 33.00 | 2,138 | 63.17 |
| Mar 2025 | 11,516 | 3,721 | 32.00 | 1,911 | 56.47 |
| Mar 2024 | 10,728 | 3,368 | 31.00 | 1,656 | 48.94 |
| Mar 2023 | 9,620 | 2,842 | 30.00 | 1,245 | 36.79 |
| Mar 2022 | 8,508 | 2,431 | 29.00 | 777.00 | 22.97 |
| Mar 2021 | 8,005 | 2,480 | 31.00 | 1,252 | 36.99 |
| Mar 2020 | 7,939 | 2,170 | 27.00 | 1,025 | 30.28 |
| Mar 2019 | 7,673 | 1,983 | 26.00 | 436.00 | 12.89 |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Sales growth | +29.0% | +3.5% | +0.8% | +6.3% | +13.1% | +11.5% | +7.3% | +21.4% |
| Operating profit growth | +47.0% | +9.4% | +14.3% | -2.0% | +16.9% | +18.5% | +10.5% | +22.5% |
| Net profit growth | -35.7% | +135.1% | +22.1% | -37.9% | +60.2% | +33.0% | +15.4% | +11.9% |
| EPS growth | -35.7% | +134.9% | +22.2% | -37.9% | +60.2% | +33.0% | +15.4% | +11.9% |
| OPM % | 26.0% | 27.0% | 31.0% | 29.0% | 30.0% | 31.0% | 32.0% | 33.0% |
Colour scale: below -5% -5% to 0% 0% to 5% 5% to 20% 20% and above. A dash means the earlier figure was zero or negative, so a percentage is not meaningful.
Shareholding
AI Analysis
No AI analysis generated yet for Torrent Pharmaceuticals.
Get Free AI Stock Analysis FREE →Latest News
-
Torrent Pharmaceuticals shares gain over 2% in today's trade - Moneycontrol.com
-
Torrent Pharmaceuticals shares gain over 2% in today's trade - Moneycontrol.com
-
Torrent Pharmaceuticals Ltd down for fifth straight session - Business Standard
-
Torrent Pharmaceuticals Ltd down for fifth straight session - business-standard.com
-
Torrent Pharmaceuticals Q1 Net Profit up 3.3% at Rs 566 Cr
-
Torrent Pharma reports Profit after tax of Rs 4920.00 Mln, in the June 2026 quarter
-
Torrent Pharmaceuticals (TRP) Earnings Surpass Expectations with 55% Revenue Growth and Strong 1Q Results - Smartkarma
-
Torrent Pharmaceuticals shares rise 2.07 percent, trading at Rs 5,064.00 - Moneycontrol.com
-
Torrent Pharmaceuticals Shares Gain 2.18% in Early Trade - Moneycontrol.com
-
Torrent Pharmaceuticals Ltd spurts 0.67%, up for five straight sessions - Business Standard
Frequently Asked Questions
What is Torrent Pharmaceuticals's current stock price?
Torrent Pharmaceuticals shares were last quoted at ₹4,654.90 (-0.0% on the day). Use the Refresh price button on this page for the latest available price. Prices are for information only.
What is the P/E ratio of Torrent Pharmaceuticals?
Torrent Pharmaceuticals has a price-to-earnings (P/E) ratio of 84.92 and a price-to-book (P/B) ratio of 20.64. The industry P/E is 53.33.
What is the 52-week high and low of Torrent Pharmaceuticals?
The 52-week high of Torrent Pharmaceuticals is ₹5,249.95 and the 52-week low is ₹3,480.00.
What is the market cap of Torrent Pharmaceuticals?
The market capitalisation of Torrent Pharmaceuticals is about ₹185,216.32 crore.
How did Torrent Pharmaceuticals perform in its latest quarterly results?
In the latest quarter (Jun 2026), Torrent Pharmaceuticals reported sales of ₹4,921.00 crore (+54.8%) and net profit of ₹566.00 crore (+3.3%), compared with the same quarter last year.
Is Torrent Pharmaceuticals a good stock to buy?
This page is for information and is not investment advice. As per the data shown here, Torrent Pharmaceuticals has a 3-year ROE of 26.00%, 3-year profit growth of 22.00%. Review the fundamentals, quarterly results and AI analysis on StockSpin, and consult a SEBI-registered adviser before investing.
What is the promoter holding in Torrent Pharmaceuticals?
Promoters hold about 60.78% of Torrent Pharmaceuticals.
Which sector does Torrent Pharmaceuticals belong to?
Torrent Pharmaceuticals belongs to the Pharmaceuticals & Drugs sector.